$29.70
+3.99%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$29.83
From 52W high−46.07%
Volume228198.00
Market cap$1.51B
P/E (TTM)—
P/S (TTM)158.0x
Div yield—
Key dataNov 4, 2026
Open
$29.83
From 52W high
−46.07%
Volume
228198.00
Market cap
$1.51B
ValuationView details →
P/E (Fwd)
192.3x
EV/EBITDA
−41.0x
P/E (TTM)
—
RSI (14)
51.3
MomentumView details →
1D Return
+3.99%
YTD Return
+28.78%
SummaryUpdated Jun 1, 2026
Nanobiotix S.A. (NASDAQ:NBTX) is a clinical-stage biotechnology company founded in 2003 and headquartered in Paris, France. The company went public on NASDAQ in December 2020. Nanobiotix specializes in developing nanotechnology-based therapeutic solutions for cancer treatment, with its lead product candidate NBTXR3 currently in advanced clinical trials. The company has established significant partnerships, most notably a global licensing agreement with Johnson & Johnson worth potentially over $2.5 billion, marking a major validation of its nanotechnology platform approach to oncology.
Similar companies
Latest newsMore news →
Nanobiotix S.A. announced final Phase 1 Study 1100 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in 24 patients with anti-PD-1-resistant advanced primary cutaneous melanoma, reporting a 41.7% overall response rate, including four complete responses, a 75% disease control rate, and median overall survival of 17.8 months.12d agoNanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.34d ago